Dyskinesia - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: D82D15BDA3FEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Dyskinesia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Dyskinesia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Dyskinesia Understanding

The DelveInsight Dyskinesia epidemiology report gives a thorough understanding of the Dyskinesia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Dyskinesia in the US, Europe, and Japan. The report covers the detailed information of the Dyskinesia epidemiology scenario in seven major countries (US, EU5, and Japan).

Dyskinesia Epidemiology Perspective by DelveInsight

The Dyskinesia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Dyskinesia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Dyskinesia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Dyskinesia Detailed Epidemiology Segmentation

The Dyskinesia epidemiology covered in the report provides historical as well as forecasted Dyskinesia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Dyskinesia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Dyskinesia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Dyskinesia Epidemiology Report and Model provide an overview of the global trends of Dyskinesia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Dyskinesia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Dyskinesia
• The report provides the segmentation of the Dyskinesia epidemiology

Report Highlights

• 11-year Forecast of Dyskinesia epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Dyskinesia
• Cases of Dyskinesia by Mutation Types
• Dyskinesia Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dyskinesia?
• What are the key findings pertaining to the Dyskinesia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Dyskinesia across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Dyskinesia?
• What are the currently available treatments of Dyskinesia?

Reasons to buy

The Dyskinesia Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Dyskinesia market
• Quantify patient populations in the global Dyskinesia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Dyskinesia therapeutics in each of the markets covered
• Understand the magnitude of Dyskinesia population by its epidemiology
• The Dyskinesia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF DYSKINESIA

3. DYSKINESIA: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Dyskinesia Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Dyskinesia Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Dyskinesia Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Dyskinesia Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Dyskinesia Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Dyskinesia Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Dyskinesia Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Dyskinesia Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Dyskinesia Treatment and Management
6.2. Dyskinesia Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Dyskinesia Epidemiology in 7MM (2019-2032)
Table 2: Dyskinesia Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Dyskinesia Epidemiology in the United States (2019-2032)
Table 4: Dyskinesia Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Dyskinesia Epidemiology in Germany (2019-2032)
Table 6: Dyskinesia Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Dyskinesia Epidemiology in France (2019-2032)
Table 8: Dyskinesia Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Dyskinesia Epidemiology in Italy (2019-2032)
Table 10: Dyskinesia Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Dyskinesia Epidemiology in Spain (2019-2032)
Table 12: Dyskinesia Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Dyskinesia Epidemiology in the United Kingdom (2019-2032)
Table 14: Dyskinesia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Dyskinesia Epidemiology in Japan (2019-2032)
Table 16: Dyskinesia Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Dyskinesia Epidemiology in 7MM (2019-2032)
Figure 2 Dyskinesia Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Dyskinesia Epidemiology in the United States (2019-2032)
Figure 4 Dyskinesia Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Dyskinesia Epidemiology in Germany (2019-2032)
Figure 6 Dyskinesia Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Dyskinesia Epidemiology in France (2019-2032)
Figure 8 Dyskinesia Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Dyskinesia Epidemiology in Italy (2019-2032)
Figure 10 Dyskinesia Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Dyskinesia Epidemiology in Spain (2019-2032)
Figure 12 Dyskinesia Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Dyskinesia Epidemiology in the United Kingdom (2019-2032)
Figure 14 Dyskinesia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Dyskinesia Epidemiology in Japan (2019-2032)
Figure 16 Dyskinesia Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report